| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259899 |
|
|
Homo sapiens |
Melanoma Cell, Non-small Cell Lung Cancer Cell |
| pmid |
sentence |
| 25685857 |
Preclinical studies described PD-1 blockade resulting in tumor growth suppression and even decreased metastasis. This has led to the development of pembrolizumab (MK-3475), a highly selective, humanized monoclonal IgG4-kappa isotype antibody against PD-1. Early clinical trials have shown high tumor response rates and long duration of effect in previously treated advanced melanoma resulting in accelerated FDA approval for the drug in this situation. Pembrolizumab has also had success in non-small cell lung cancer and is being tested in multiple other tumor types. |
|
4.0
pembrolizumab
binding